Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAmp DFDA64E 92D 366? 2CC6DE65 27E6C 2==6865=J @A6?:?8 ...

Regeneron Pharmaceuticals, Inc. announced that it will present new and updated data from its oncology and hematology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

The festival will open with ASCO: Without Permission, written and directed by Travis Gutiérrez Senger, executive produced by Gael García Bernal and Diego Luna, and featuring special appearances ...

Allogene Therapeutics, a clinical-stage biotechnology company, will present updated data from its Phase 1 TRAVERSE trial of ALLO-316 at the 2025 ASCO Annual Meeting in Chicago. The study focuses ...

In this press release, forward-looking statements include statements concerning the timing and content of Corcept’s presentation at ASCO and cortisol’s potential to treat patients with ovarian ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell therapies for solid tumors. The recent American Society of Clinical ...

In the 1970s and ‘80s, traces of the artist collective Asco, named after the Spanish word for “disgust,” could be seen all over East L.A. The then-teenage creatives pulled all kinds of high ...

Key findings on renal cell carcinoma (RCC) presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium include the final results of the CheckMate 9ER and COSMIC-313 ...

They called themselves Asco, the Spanish word for nausea or revulsion. Then, a little more than a decade on, Asco vanished. Almost. The new documentary ASCO: Without Permission, premiering at ...

ASCO GU symposium focuses on antibody-drug conjugates, biomarker advancements, and disparities research in genitourinary cancers. TALAPRO-2 trial results highlight talazoparib and enzalutamide as ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU ...

Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS ...